SARS-CoV-2 serosurvey in health care workers of the Veneto Region
Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investi...
Saved in:
Published in | Clinical chemistry and laboratory medicine Vol. 58; no. 12; pp. 2107 - 2111 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
De Gruyter
26.08.2020
Walter De Gruyter & Company |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs). Methods Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China). Results A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1-5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects. Conclusions Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers. |
---|---|
AbstractList | Abstract
Objectives
The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs).
Methods
Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China).
Results
A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1–5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects.
Conclusions
Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers. The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs).Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China).A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1–5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects.Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers. Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs). Methods Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China). Results A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1-5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects. Conclusions Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers. |
Author | Fedeli, Ugo Padoan, Andrea Lo Cascio, Giuliana Porru, Stefano Plebani, Mario Schievano, Elena Palù, Giorgio Lippi, Giuseppe Vecchiato, Elena |
Author_xml | – sequence: 1 givenname: Mario orcidid: 0000-0002-0270-1711 surname: Plebani fullname: Plebani, Mario email: mario.plebani@unipd.it organization: Department of Medicine-DIMED, University of Padova, Padova, Italy – sequence: 2 givenname: Andrea orcidid: 0000-0003-1284-7885 surname: Padoan fullname: Padoan, Andrea organization: Department of Medicine-DIMED, University of Padova, Padova, Italy – sequence: 3 givenname: Ugo surname: Fedeli fullname: Fedeli, Ugo organization: Epidemiological Department, Azienda Zero, Veneto Region, Padova, Italy – sequence: 4 givenname: Elena surname: Schievano fullname: Schievano, Elena organization: Epidemiological Department, Azienda Zero, Veneto Region, Padova, Italy – sequence: 5 givenname: Elena surname: Vecchiato fullname: Vecchiato, Elena organization: Department of Information Technology, Azienda Zero, Veneto Region, Padova, Italy – sequence: 6 givenname: Giuseppe orcidid: 0000-0001-9523-9054 surname: Lippi fullname: Lippi, Giuseppe organization: Section of Clinical Biochemistry, University of Verona, Verona, Italy – sequence: 7 givenname: Giuliana surname: Lo Cascio fullname: Lo Cascio, Giuliana organization: Department of Microbiology and Virology, University of Verona, Verona, Italy – sequence: 8 givenname: Stefano surname: Porru fullname: Porru, Stefano organization: Department of Diagnostics and Public Health, University of Verona, Verona, Italy – sequence: 9 givenname: Giorgio surname: Palù fullname: Palù, Giorgio organization: University of Padova, Azienda Zero, Veneto Region, Padova, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32845861$$D View this record in MEDLINE/PubMed |
BookMark | eNptkE1rGzEQhkVJqZO01x6DIJdclGr0sdq9BIzJR8FQiFtfl13tKLazXiXSboL_fbS120DpaebwzDszzwk56nyHhHwFfgka9Ddr2y0TXHAGQmYfyDEoaZiSEo5-94plmYAJOYlxwzlorcwnMpEiVzrP4JhMF9P7BZv5JRM0YvBxCC-4o-uOrrBq-xW1VUD66sMjhki9o_0K6RI77D29x4e17z6Tj65qI3451FPy6-b65-yOzX_cfp9N58xqKXpmaqilFFo3RudV0whAx2trramVRFU465SDTDZCF-iyAmrrascrwzObF9bIU3Kxz30K_nnA2JfbdbTYtlWHfoilSI_nqigKSOj5P-jGD6FL1yVK58JkHMbAyz1l09sxoCufwnpbhV0JvBzllqPccpRbjnLTwNkhdqi32PzF_9hMwNUeeE3qMDT4EIZdat7X_z9Z5yAEcCPfAIx2iZ4 |
CitedBy_id | crossref_primary_10_1038_s41598_021_89877_y crossref_primary_10_1515_almed_2023_0008 crossref_primary_10_1016_j_puhe_2021_07_029 crossref_primary_10_2478_pjph_2022_0001 crossref_primary_10_4103_jfmpc_jfmpc_288_21 crossref_primary_10_1001_jamanetworkopen_2021_15699 crossref_primary_10_1136_bmjopen_2020_046276 crossref_primary_10_1016_j_idh_2021_03_004 crossref_primary_10_3390_vaccines9080824 crossref_primary_10_1016_j_infpip_2023_100297 crossref_primary_10_1371_journal_pone_0264964 crossref_primary_10_1002_eji_202049058 crossref_primary_10_1515_chem_2023_0364 crossref_primary_10_3390_idr13030067 crossref_primary_10_3390_v14122652 crossref_primary_10_1016_j_ebiom_2020_103087 crossref_primary_10_33631_duzcesbed_849590 crossref_primary_10_3390_biomedicines11010160 crossref_primary_10_1016_j_jhin_2021_04_021 crossref_primary_10_1515_labmed_2021_0107 crossref_primary_10_1097_j_pbj_0000000000000166 crossref_primary_10_1177_0300891620974755 crossref_primary_10_1016_j_eclinm_2021_100770 crossref_primary_10_1136_bmjopen_2020_047010 crossref_primary_10_1097_QCO_0000000000000734 crossref_primary_10_1016_j_ijid_2021_09_023 crossref_primary_10_3390_ijerph18073343 crossref_primary_10_1515_cclm_2021_0038 crossref_primary_10_3389_fmed_2021_689994 crossref_primary_10_3390_vaccines8040778 crossref_primary_10_1097_MD_0000000000032992 crossref_primary_10_1515_cclm_2020_1758 crossref_primary_10_1038_s41598_021_89014_9 crossref_primary_10_1136_bmjopen_2021_052130 crossref_primary_10_3390_v15040955 crossref_primary_10_3390_v13061064 crossref_primary_10_3390_ijerph18126446 crossref_primary_10_1515_cclm_2020_1681 crossref_primary_10_1038_s41598_021_04279_4 crossref_primary_10_1016_j_ebiom_2021_103259 crossref_primary_10_3390_ijerph18094761 crossref_primary_10_1111_all_15047 crossref_primary_10_1515_almed_2023_0036 crossref_primary_10_1017_S0950268822000280 crossref_primary_10_3390_ijerph18052567 crossref_primary_10_3390_v13020347 crossref_primary_10_2139_ssrn_3907251 crossref_primary_10_1016_j_jhin_2020_11_008 crossref_primary_10_3390_ijerph18084376 crossref_primary_10_1515_cclm_2022_0948 |
Cites_doi | 10.1001/jamainternmed.2020.4214 10.7326/M20-1301 10.1515/cclm-2020-0443 10.1101/2020.03.16.20035014 10.1001/jama.2020.14765 10.1126/science.abc1227 10.1093/labmed/lmaa025 10.1038/s41591-020-0897-1 10.1515/cclm-2020-0749 10.1016/j.it.2020.03.007 10.1001/jama.2020.11160 10.1016/j.cell.2020.05.015 10.1001/jama.2020.4683 10.1016/j.cca.2020.04.026 10.1001/jama.2020.8259 10.1056/NEJMc2011599 10.1093/cid/ciaa310 10.1038/s41591-020-0913-5 10.1515/cclm-2020-0473 10.1515/cclm-2020-0880 10.2807/1560-7917.ES.2020.25.10.2000180 10.1101/2020.05.12.20098236 10.1016/j.jcv.2020.104545 10.1016/S1473-3099(20)30196-1 10.2139/ssrn.3546052 10.1016/j.cca.2020.05.050 10.1515/cclm-2020-1096 10.1101/2020.04.17.20061440 10.2807/1560-7917.ES.2020.25.3.2000045 |
ContentType | Journal Article |
Copyright | 2020. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2020. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7T7 7TK 7U7 8FD C1K FR3 P64 7X8 |
DOI | 10.1515/cclm-2020-1236 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | CrossRef Biotechnology Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry |
EISSN | 1437-4331 |
EndPage | 2111 |
ExternalDocumentID | 10_1515_cclm_2020_1236 32845861 10_1515_cclm_2020_123658122107 |
Genre | Journal Article |
GeographicLocations | Italy |
GeographicLocations_xml | – name: Italy |
GroupedDBID | --- 0R~ 0~D 29B 354 36B 4.4 53G 5GY 5RE AAAEU AABBZ AAEMA AAFPC AAGVJ AALGR AAOQK AAOWA AAPJK AAQCX AASQH AAXCG ABAOT ABAQN ABFKT ABFQV ABIQR ABLJU ABMIY ABPLS ABPTK ABRDF ABUVI ABXMZ ABYBW ACEFL ACGFS ACIWK ACPRK ACTFP ACZBO ADDWE ADEQT ADGQD ADGYE ADOZN AEDGQ AEGVQ AEICA AEJTT AENEX AEQDQ AERZL AEXIE AFBAA AFBQV AFCXV AFGDO AFQUK AFRAH AFYRI AHOVO AHVWV AHXUK AIERV AIGSN AJATJ AJHHK ALMA_UNASSIGNED_HOLDINGS ALUKF ASYPN BAKPI BBCWN BCIFA CAG CGQUA CS3 DBYYV DU5 EBS EMOBN F5P HZ~ ITC IY9 M48 N9A O9- OBC OBS OEB OES OHH P2P PQEST PQQKQ QD8 RDG SA. UK5 WTRAM ZA5 AAILP ABJNI ABVMU ABWLS ACPMA AGBEV AKXKS ALYBR CGR CUY CVF ECM EIF KDIRW NPM SLJYH TEORI AAYXX CITATION 7QO 7T7 7TK 7U7 8FD C1K FR3 P64 7X8 |
ID | FETCH-LOGICAL-c532t-7b1b33255d758add21ef0bccc7b43e49fcf4f163d259ef691bcfbf0a706c89c73 |
ISSN | 1434-6621 |
IngestDate | Fri Oct 25 10:56:21 EDT 2024 Thu Oct 10 20:29:32 EDT 2024 Thu Sep 26 17:15:01 EDT 2024 Sat Sep 28 08:29:26 EDT 2024 Fri Nov 25 00:39:07 EST 2022 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | COVID-19 seroprevalence health care workers SARS-CoV-2 antibody |
Language | English |
License | This work is licensed under the Creative Commons Attribution 4.0 International License. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c532t-7b1b33255d758add21ef0bccc7b43e49fcf4f163d259ef691bcfbf0a706c89c73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-9523-9054 0000-0003-1284-7885 0000-0002-0270-1711 |
OpenAccessLink | http://www.degruyter.com/doi/10.1515/cclm-2020-1236 |
PMID | 32845861 |
PQID | 2458276017 |
PQPubID | 105421 |
PageCount | 05 |
ParticipantIDs | proquest_miscellaneous_2437849991 proquest_journals_2458276017 crossref_primary_10_1515_cclm_2020_1236 pubmed_primary_32845861 walterdegruyter_journals_10_1515_cclm_2020_123658122107 |
PublicationCentury | 2000 |
PublicationDate | 2020-08-26 |
PublicationDateYYYYMMDD | 2020-08-26 |
PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-26 day: 26 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Berlin |
PublicationTitle | Clinical chemistry and laboratory medicine |
PublicationTitleAlternate | Clin Chem Lab Med |
PublicationYear | 2020 |
Publisher | De Gruyter Walter De Gruyter & Company |
Publisher_xml | – name: De Gruyter – name: Walter De Gruyter & Company |
References | 2023033111431160648_j_cclm-2020-1236_ref_030 2023033111431160648_j_cclm-2020-1236_ref_003 2023033111431160648_j_cclm-2020-1236_ref_025 2023033111431160648_j_cclm-2020-1236_ref_004 2023033111431160648_j_cclm-2020-1236_ref_026 2023033111431160648_j_cclm-2020-1236_ref_005 2023033111431160648_j_cclm-2020-1236_ref_027 2023033111431160648_j_cclm-2020-1236_ref_006 2023033111431160648_j_cclm-2020-1236_ref_028 2023033111431160648_j_cclm-2020-1236_ref_021 2023033111431160648_j_cclm-2020-1236_ref_022 2023033111431160648_j_cclm-2020-1236_ref_001 2023033111431160648_j_cclm-2020-1236_ref_023 2023033111431160648_j_cclm-2020-1236_ref_002 2023033111431160648_j_cclm-2020-1236_ref_024 2023033111431160648_j_cclm-2020-1236_ref_007 2023033111431160648_j_cclm-2020-1236_ref_029 2023033111431160648_j_cclm-2020-1236_ref_008 2023033111431160648_j_cclm-2020-1236_ref_009 2023033111431160648_j_cclm-2020-1236_ref_020 2023033111431160648_j_cclm-2020-1236_ref_014 2023033111431160648_j_cclm-2020-1236_ref_015 2023033111431160648_j_cclm-2020-1236_ref_016 2023033111431160648_j_cclm-2020-1236_ref_017 2023033111431160648_j_cclm-2020-1236_ref_010 2023033111431160648_j_cclm-2020-1236_ref_011 2023033111431160648_j_cclm-2020-1236_ref_012 2023033111431160648_j_cclm-2020-1236_ref_013 2023033111431160648_j_cclm-2020-1236_ref_018 2023033111431160648_j_cclm-2020-1236_ref_019 |
References_xml | – ident: 2023033111431160648_j_cclm-2020-1236_ref_020 doi: 10.1001/jamainternmed.2020.4214 – ident: 2023033111431160648_j_cclm-2020-1236_ref_002 doi: 10.7326/M20-1301 – ident: 2023033111431160648_j_cclm-2020-1236_ref_008 doi: 10.1515/cclm-2020-0443 – ident: 2023033111431160648_j_cclm-2020-1236_ref_016 doi: 10.1101/2020.03.16.20035014 – ident: 2023033111431160648_j_cclm-2020-1236_ref_021 doi: 10.1001/jama.2020.14765 – ident: 2023033111431160648_j_cclm-2020-1236_ref_006 doi: 10.1126/science.abc1227 – ident: 2023033111431160648_j_cclm-2020-1236_ref_007 doi: 10.1093/labmed/lmaa025 – ident: 2023033111431160648_j_cclm-2020-1236_ref_024 doi: 10.1038/s41591-020-0897-1 – ident: 2023033111431160648_j_cclm-2020-1236_ref_010 doi: 10.1515/cclm-2020-0749 – ident: 2023033111431160648_j_cclm-2020-1236_ref_028 doi: 10.1016/j.it.2020.03.007 – ident: 2023033111431160648_j_cclm-2020-1236_ref_019 doi: 10.1001/jama.2020.11160 – ident: 2023033111431160648_j_cclm-2020-1236_ref_026 doi: 10.1016/j.cell.2020.05.015 – ident: 2023033111431160648_j_cclm-2020-1236_ref_001 doi: 10.1001/jama.2020.4683 – ident: 2023033111431160648_j_cclm-2020-1236_ref_014 doi: 10.1016/j.cca.2020.04.026 – ident: 2023033111431160648_j_cclm-2020-1236_ref_013 doi: 10.1001/jama.2020.8259 – ident: 2023033111431160648_j_cclm-2020-1236_ref_022 doi: 10.1056/NEJMc2011599 – ident: 2023033111431160648_j_cclm-2020-1236_ref_012 doi: 10.1093/cid/ciaa310 – ident: 2023033111431160648_j_cclm-2020-1236_ref_005 doi: 10.1038/s41591-020-0913-5 – ident: 2023033111431160648_j_cclm-2020-1236_ref_015 doi: 10.1515/cclm-2020-0473 – ident: 2023033111431160648_j_cclm-2020-1236_ref_030 doi: 10.1515/cclm-2020-0880 – ident: 2023033111431160648_j_cclm-2020-1236_ref_023 – ident: 2023033111431160648_j_cclm-2020-1236_ref_003 doi: 10.2807/1560-7917.ES.2020.25.10.2000180 – ident: 2023033111431160648_j_cclm-2020-1236_ref_025 doi: 10.1101/2020.05.12.20098236 – ident: 2023033111431160648_j_cclm-2020-1236_ref_018 doi: 10.1016/j.jcv.2020.104545 – ident: 2023033111431160648_j_cclm-2020-1236_ref_017 doi: 10.1016/S1473-3099(20)30196-1 – ident: 2023033111431160648_j_cclm-2020-1236_ref_011 doi: 10.2139/ssrn.3546052 – ident: 2023033111431160648_j_cclm-2020-1236_ref_009 doi: 10.1016/j.cca.2020.05.050 – ident: 2023033111431160648_j_cclm-2020-1236_ref_029 doi: 10.1515/cclm-2020-1096 – ident: 2023033111431160648_j_cclm-2020-1236_ref_027 doi: 10.1101/2020.04.17.20061440 – ident: 2023033111431160648_j_cclm-2020-1236_ref_004 doi: 10.2807/1560-7917.ES.2020.25.3.2000045 |
SSID | ssj0015547 |
Score | 2.543897 |
Snippet | Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable... Abstract Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses... The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges... |
SourceID | proquest crossref pubmed walterdegruyter |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2107 |
SubjectTerms | Adult Antibodies Antigens Asymptomatic Betacoronavirus - immunology Biomedical engineering Chemiluminescence Coronaviridae Coronaviruses COVID-19 Female Health care health care workers Health Personnel - statistics & numerical data Health services Humans Immunoglobulin G Immunoglobulin M Infections Italy Luminescent Measurements Male Medical personnel Middle Aged Polymerase chain reaction Respiratory diseases Reverse transcription Risk groups SARS-CoV-2 SARS-CoV-2 antibody Seroconversion Seroepidemiologic Studies seroprevalence Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Subpopulations Viral diseases |
Title | SARS-CoV-2 serosurvey in health care workers of the Veneto Region |
URI | http://www.degruyter.com/doi/10.1515/cclm-2020-1236 https://www.ncbi.nlm.nih.gov/pubmed/32845861 https://www.proquest.com/docview/2458276017 https://search.proquest.com/docview/2437849991 |
Volume | 58 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKJvHxMMH4KgwUJCQepmyNk9jOY6naTWgbaP3Q3qLEOZdJI0FdC4I_gL-bc2yn7Toh4CWKnCi27n453_m-CHmrBGMgQuUzJRI_ymTh50yfiCXAJQOeiEyfQ56eseNx9OEivmi1fq1ELS3m-YH8eWteyf9wFceQrzpL9h8423wUB_Ae-YtX5DBe_4rHw-750O9VE5_u43zV9WL2Deo8PpPdWJedrpvB6CxdGwwwQeGG-uY5TB1HXJ0ClyMpXQ-42rFgUaJd8Tf98J-uIDctoXTKjwnoMu6oosrKJlyyEfwDKMBkY4-nzctD-fkSUJ2vTJAZmG7e7iCC1mFwJtvdiLvavY9icv9otvihbzV2N6Qa6meRz5hJiz4AN8aXqVtWLMdiFX50TciaRrl2w6ZWXG9sBnFdN0PKqy9-vV5daGa57TlX_9nHdDA-OUlH_YvRHbJNUWChpNzuHr3vTxp_FCpddZset3hb_hNnOFz__rp6s2GzPCA732s6FTA1VFrRZkYPyY41Q7yuwdQj0oJyl9zrOc7vkrunltmPcedtYOYtYeZdlp6Bmadh5lmYeZXyEGaegZlnYPaEjAf9Ue_Yt503fBmHdO7zPMjDEK3NAs1J3AFpAKqTSyl5HoUQJUqqSKEmX6DxDIolQS5VrjoZ7zApEsnDp2SrrEp4TjzBhSgyRWUsaFQUnSwDBkUWZQEFCDqiTd45gqVfTYGVVBumSNpUkzbVpE01adtkz9EztT_hdUq131fHdfE2edM8Rlppv1dWQrXQ74RcaMs-aJNnhg_NVCGqZ7Fg-ITfYMxyjtuXE6NqrJH44s_LeknuL3-WPbI1ny3gFeqx8_y1BdlvpdmdYg |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Walter de Gruyter |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+serosurvey+in+health+care+workers+of+the+Veneto+Region&rft.jtitle=Clinical+chemistry+and+laboratory+medicine&rft.au=Plebani%2C+Mario&rft.au=Padoan%2C+Andrea&rft.au=Fedeli%2C+Ugo&rft.au=Schievano%2C+Elena&rft.date=2020-08-26&rft.pub=Walter+De+Gruyter+%26+Company&rft.issn=1434-6621&rft.eissn=1437-4331&rft.volume=58&rft.issue=12&rft.spage=2107&rft.epage=2111&rft_id=info:doi/10.1515%2Fcclm-2020-1236&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon |